How do pharma, biotech and MedTech manufacturers achieve lasting inspection readiness toward FDA, EMA and BfArM?
We systematically prepare manufacturing sites, QA teams and documentation for inspections by FDA, EMA, BfArM and notified bodies: gap analysis, mock inspection by experienced auditors, staff coaching and back-room support during the live inspection. The real lever is not last-minute preparation right before the date, but a quality system that is inspection-ready every single day. Anyone who runs inspection readiness as a permanent state rather than a project will get through even an unannounced inspection without panic.
- Pharma
- Biotech
- MedTech
- IVD
Overview
What risks arise before a regulatory inspection?
Mock inspections and back-room support by experienced former auditors · EU GMP Guide incl. Annex 11, FDA 21 CFR Part 211, MDR (EU 2017/745)
Last updated: 2026-06-13
Inspections by FDA, EMA, BfArM and notified bodies are critical events: findings can range from written observations to a production halt, recall or withdrawal of the manufacturing authorisation. The typical weak points where inspections fail:
- GMP documentation is incomplete or not up to date. QMS documents, batch records and validation files must meet the requirements of the EU GMP Guide and FDA 21 CFR Part 211 at all times, not only on the day of the inspection.
- Data integrity is not consistently demonstrable. Authorities increasingly review the completeness and traceability of electronic records under Annex 11 of the EU GMP Guide and FDA 21 CFR Part 11.
- Open CAPAs from previous audits have not been closed. An unimplemented corrective action plan is a direct signal to inspectors of a weak quality system.
- Staff are not prepared for inspection situations. Hesitant answers to auditor questions, slow document retrieval and inconsistent statements under time pressure generate findings the system itself would not warrant.
- In MedTech and IVD, the QM system lacks inspection readiness under ISO 13485:2016, as does the technical documentation toward notified bodies under MDR (EU) 2017/745 and IVDR (EU) 2017/746.
Services
How we support you
Readiness Assessment & Gap Analysis
Systematic assessment of inspection preparedness across documentation, CAPA status, data integrity, training level and facilities. The result is a prioritised action plan with a timeline up to the inspection.
Mock Inspection
Realistic simulation of a regulatory inspection by experienced former auditors: document review, staff interviews and facility walkthrough. The result is a written findings report with CAPA recommendations.
Learn more →Inspection Coaching for QA & Production
Preparing QA management, production staff and management for inspection situations: practising typical auditor questions, facility walkthroughs and document presentation under time pressure, with a concrete code of conduct for the inspection day.
On-Site Support During the Inspection
Back-room support by experienced consultants during the live inspection: rapid document retrieval, real-time advice and coordination between front room, back room and the authority. The result is orderly inspection management instead of improvisation.
CAPA and Finding Management After the Inspection
Structured processing of inspection findings into a robust CAPA plan with root cause analysis, deadlines and effectiveness checks that meets the regulatory response deadline.
Learn more →How we work together
What it comes down to
Inspection readiness is not a document but a state. Three strands have to fit together, and in this order: first, the GMP documentation under the EU GMP Guide and FDA 21 CFR Part 211 must be complete and current, because without reliable records there is nothing to present. Data integrity under Annex 11 and 21 CFR Part 11 builds on top of this, because inspectors review not only the result but its traceability. Only once both are in place does it pay off to train the teams for the inspection situation, because a staff member can only confidently present what actually exists. Anyone who starts with coaching before the documentation holds up is training people to show off gaps.
This is precisely why the gap analysis comes first: it reveals which strand is the bottleneck before effort flows into the mock inspection and coaching. Open CAPAs from previous audits are the first touchstone here, because an unclosed corrective action plan is the clearest signal to inspectors of a weak quality system. The difference between an inspection passed with composure and a frantic one rarely lies on the day itself, but in whether the system was already inspection-ready every day beforehand.
Our approach
Our approach
Step
Result
Readiness Assessment & Gap Analysis
Prioritised action plan: where documentation, data integrity and CAPA status stand against GMP, and what is critical before the inspection.
Gap Closure & Data Integrity
Updated QMS documentation, closed legacy CAPAs and demonstrable data integrity under Annex 11 and 21 CFR Part 11.
Mock Inspection
Findings report from a simulated inspection by experienced auditors, with CAPA recommendations ahead of the real date.
Staff Coaching
Trained teams that handle auditor questions, facility walkthroughs and document presentation under time pressure.
Inspection Support
Front-room and back-room structure in operation, orderly document retrieval and real-time advice during the inspection.
Finding Resolution
Timely CAPA plan with root cause analysis and effectiveness check as the regulatory response.
Common pitfalls
Where projects commonly fail
Inspection readiness is treated as a one-off project shortly before an announced date.
An unannounced FDA or regulatory inspection then hits a system that was only tidied up for the planned cut-off date. Lasting inspection readiness comes only from a quality system that holds up every day.
Open CAPAs from previous audits are left unresolved until just before the inspection.
An uncompleted or ineffective corrective action plan is a direct indicator to inspectors of a weak quality system and regularly triggers follow-on findings.
Data integrity is underestimated.
Authorities review the completeness and traceability of electronic records under Annex 11 of the EU GMP Guide and FDA 21 CFR Part 11; missing audit trails or uncontrolled Excel spreadsheets are a frequent finding.
Staff are not prepared for the inspection situation.
Hesitant or contradictory answers to auditor questions and slow document retrieval generate findings even though the underlying system is compliant. The inspection also assesses how confidently the team performs.
There is no separate front-room and back-room organisation.
Without clear roles, document coordination and a calm back room for research, the live inspection produces panic, off-the-cuff commitments and avoidable statements to the authority.
FAQ
Frequently asked questions
Sources
- EU GMP Guide (EudraLex Volume 4), incl. Annex 11: primary text
- FDA 21 CFR Part 211 (cGMP for Finished Pharmaceuticals) and 21 CFR Part 11 (Electronic Records): primary text
- Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR): primary text
- ISO 13485:2016: Quality management systems for medical devices
- Writer source material on Inspection Readiness (entourage-website-writer)
- https://theentourage.de/expertise/inspection-readiness/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Related insights
All insights →Regulations & standards considered
- EU GMP Guide (EudraLex Volume 4)
- EU GMP Guide Annex 11 (Computerised Systems)
- FDA 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)
- FDA 21 CFR Part 11 (Electronic Records, Electronic Signatures)
- MDR (EU) 2017/745
- IVDR (EU) 2017/746
- ISO 13485:2016 (Quality management system for medical devices)
Related topics
Mock Audits →
Trial inspection by experienced auditors before the real date
Good Manufacturing Practice (GMP) →
A GMP system under the EU GMP Guide and 21 CFR Part 211 as the foundation
CAPA Management →
Close open CAPAs and resolve findings on time
GxP Audit Consulting →
Regulatory GxP audits beyond the regulatory inspection
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences